Stay updated with breaking news from Assist Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing...
– Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 – – Advanced IND-enabling...
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Mind Medicine(NASDAQ:NASDAQ:MNMD) Q1 2022 Earnings Conference Call May16, 2022, 08:30AM ET Company Participants Rob Barrow - CEO Dan Karlin - Chief Medical Officer Miri Halperin Wernli -...
/PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing...